Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2
Detection Principle
ImmunoAssay-Antigen
Target
nucleocapsid protein
Testing Method Category
LFIA
Testing Method
Panbio COVID-19 Ag rapid test device by Abbott (Lake Country, IL, U.S.A)
Testing Method - Additional Info
Evaluation of Panbio test compared with results from Allplex 19-nCoV multiplex platform for detection of SARS-CoV-2 (Seegene, South-Korea)
Reported Performance
Specificity: 100% ; Sensitivity: 95.2% (Utrecht samples), 98.0% (Aruba samples) ; remarks: more sensitivity values are available for both sets of samples and for different Ct values
Sample Size
1575 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements